Merck & Co (MRK)

Merck (NYSEMRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug regimen of doravirine/islatravir [DOR/ISL (100mg/0.25mg)] in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei [BIC/FTC/TAF (50mg/200mg/25mg)] in trial MK-8591A-052) or antiretroviral therapy [baseline antiretroviral therapy (bART)] in trial MK-8591A-051. In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objectives at Week 48. The findings will be shared in late-breaking oral presentations at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI) being held in San Francisco and were featured in a CROI press conference. Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options

Merck (NYSEMRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.

NEW YORK, March 10, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FMC Corporation (NYSEFMC), Elastic N.V. NYSE:ESTCNYSEESTC)(NASDAQ:NTLANASDAQNTLA, and Merck & Co., Inc. (NYSE: MRKNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) --

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Glancy Prongay & Murray LLP reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”).

Law Offices of Howard G. Smith reminds investors of the upcoming April 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”).

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) --

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Edison International (NYSEEIX), Elastic N.V. NYSE:ESTCNYSEESTC)(NASDAQ:NTLANASDAQNTLA, and Merck & Co., Inc. (NYSE: MRKNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. (“Merck” or “the Company”) (NYSEMRK) and certain of its officers.

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.

NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Merck (NYSEMRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC) as neoadjuvant treatment, then continued as adjuvant treatment in combination with standard of care radiotherapy with or without cisplatin and then as a single agent. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of June 23, 2025.

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Merck & Co (“Merck” or the “Company”) (NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.

Merck (NYSEMRK), known as MSD outside of the United States and Canada, announced today that Caroline Litchfield, executive vice president and chief financial officer, and Dr. Dean Y. Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m. EST.

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Merck & Co (“Merck” or the “Company”) (NYSEMRK) securities between February 3, 2022, to February 3, 2025, inclusive (the “Class Period”). Merck investors have until April 14, 2025 to file a lead plaintiff motion.

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) --

Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSEMRK) investors concerning the Company’s possible violations of the federal securities laws.

Law Offices of Howard G. Smith announces an investigation on behalf of Merck & Co (“Merck” or the “Company”) (NYSEMRK) investors concerning the Company’s possible violations of federal securities laws.

The Law Offices of Frank R. Cruz announces an investigation of Merck & Co (“Merck” or the “Company”) (NYSEMRK) on behalf of investors concerning the Company’s possible violations of federal securities laws.

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Merck & Co., Inc. (“Merck” or the “Company”) (NYSEMRK) between February 3, 2022 and February 3, 2025, inclusive.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Merck To Contact Him Directly To Discuss Their Options